Titan Pharma in talks with Braeburn about future of Probuphine partnership

Titan Pharma in talks with Braeburn about future of Probuphine partnership

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid dependence. 

Read More

CIBC-favored health care stocks for 2018

CIBC-favored health care stocks for 2018

For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps.

Read More

Eiger completes enrollment in Phase 2 ULTRA study

Eiger completes enrollment in Phase 2 ULTRA study

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54 patients were enrolled across sites in the U.S. and Australia.

Read More